Equity Overview
Price & Market Data
Price: $1.54
Daily Change: $0.00 / 0.00%
Daily Range: $1.50 - $1.56
Market Cap: $129,995,384
Daily Volume: 590,077
Performance Metrics
1 Week: 5.52%
1 Month: -32.00%
3 Months: 19.53%
6 Months: -23.12%
1 Year: 14.18%
YTD: -35.17%
Company Details
Employees: 33
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.